Overview
- Peptide (C)HEAWHFVRMVELN, corresponding to amino acid residues 202 - 214 of mouse BDKRB1 (Accession Q61125). Extracellular, 2nd loop.
B1 Bradykinin Receptor (BDKRB1) (extracellular) Blocking Peptide (#BLP-BR013)
- Western blot analysis of rat brain lysate (lanes 1 and 4), mouse brain lysate (lanes 2 and 5) and rat heart lysate (lanes 3 and 6):1-3. Anti-B1 Bradykinin Receptor (BDKRB1) (extracellular) Antibody (#ABR-013), (1:500).
4-6. Anti-B1 Bradykinin Receptor (BDKRB1) (extracellular) Antibody, preincubated with B1 Bradykinin Receptor (BDKRB1) (extracellular) Blocking Peptide (BLP-BR013). - Western blot analysis of mouse BV-2 microglia cell line lysate (lanes 1 and 5), mouse J774 macrophage cell line lysate (lanes 2 and 6), mouse M1 myeloid leukemia cell line lysate (lanes 3 and 7) and mouse Neuro-2a neuroblastoma cell line lysate (lanes 4 and 8):1-4. Anti-B1 Bradykinin Receptor (BDKRB1) (extracellular) Antibody (#ABR-013), (1:400).
5-8. Anti-B1 Bradykinin Receptor (BDKRB1) (extracellular) Antibody, preincubated with B1 Bradykinin Receptor (BDKRB1) (extracellular) Blocking Peptide (BLP-BR013).
- Cell surface detection of B1 Bradykinin Receptor by indirect flow cytometry in live intact mouse BV-2 microglia cell line:___ Cells.
___ Cells + goat-anti-rabbit-FITC.
___ Cells + Anti-B1 Bradykinin Receptor (BDKRB1) (extracellular) Antibody (#ABR-013), (5μg) + goat-anti-rabbit-FITC.
- Walker, K. et al. (1995) Neurochem. Int. 26, 1.
- Böckmann, S. and Paegelow, I. (2000) J. Leukoc. Biol. 68, 587.
- Hess, J.F. et al. (2004) J. Pharmacol. Exp. Ther. 310, 488.
Kinins are small peptides rapidly produced following tissue injury that serve as important modulators of inflammation and pain. In the periphery, the actions of kinins include vasodilatation, increased vascular permeability, stimulation of immune cells, and induction of pain. Kinins in the central nervous system (CNS) appear to initiate a similar cascade of events leading to neural tissue damage as well as long lasting disturbances affecting blood-brain barrier function.1
Kinins such as Bradykinin (BK), Lys-BK, desArg9-BK, and Lys-desArg9-BK exert their action via two distinct receptors: the B1 Bradykinin receptor (BKRB1) and the B2 Bradykinin receptor (BKRB2). The desArg9-BK and Lys-desArg9-BK peptides activate BKRB1 while BK and Lys-BK operate by activating BKRB2.2 Both BKRB1 and BKRB2 are members of the seven-transmembrane domain, G protein-coupled receptor (GPCR) superfamily and share a common structure of seven putative transmembrane domains, an extracellular amino terminus, and a cytoplasmic carboxyl terminus.
Expression of BKRB1is inducible upon various types of tissue injury and by inflammatory mediators such as bacterial lipopolysaccharide (LPS) and cytokines. BKRB1 was long considered not to be expressed in healthy tissues. However, recent work has demonstrated a low level of expression of BKRB1 in the CNS of rodent and primates. In contrast, BKRB2 is constitutively expressed on various cell types.3 BKRB1 represents a potential therapeutic target for treatment of inflammatory disorders and cardiovascular diseases.
Application key:
Species reactivity key:
Anti-B1 Bradykinin Receptor (BDKRB1) (extracellular) Antibody (#ABR-013) is a highly specific antibody directed against an extracellular epitope of the mouse protein. The antibody can be used in western blot and indirect flow cytometry applications. It has been designed to recognize B1 Bradykinin Receptor from mouse and rat samples. The antibody won’t recognize human samples.